ACELYRIN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.06 USD | -2.17% |
|
-7.94% | -45.58% |
| Jul. 01 | Acelyrin, Inc.(NasdaqGS:SLRN) added to Russell 3000E Index | CI |
| Jul. 01 | Acelyrin, Inc.(NasdaqGS:SLRN) added to Russell Microcap Index | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 726.2 | 402 | - | - |
| Enterprise Value (EV) 1 | 508.1 | 526.2 | 331.3 | 402 |
| P/E ratio | -1.37 x | -1.34 x | -1.01 x | -1.22 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 17.6 x |
| EV / Revenue | - | - | - | 17.6 x |
| EV / EBITDA | -1.2 x | -1.26 x | -0.76 x | - |
| EV / FCF | -2.95 x | -2.08 x | -0.89 x | -0.87 x |
| FCF Yield | -33.9% | -48% | -112% | -115% |
| Price to Book | 1.11 x | -1.71 x | -14 x | - |
| Nbr of stocks (in thousands) | 97,339 | 99,027 | - | - |
| Reference price 2 | 7.460 | 4.060 | 4.060 | 4.060 |
| Announcement Date | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 22.86 |
| EBITDA 1 | - | -421.9 | -416.4 | -437.4 | - |
| EBIT 1 | - | -422.1 | -363.7 | -425 | -490.9 |
| Operating Margin | - | - | - | - | -2,147.2% |
| Earnings before Tax (EBT) 1 | - | -381.6 | -301.8 | -393.4 | -460.8 |
| Net income 1 | -64.77 | -381.6 | -301.8 | -393.4 | -460.8 |
| Net margin | - | - | - | - | -2,015.88% |
| EPS 2 | -21.09 | -5.430 | -3.034 | -4.023 | -3.326 |
| Free Cash Flow 1 | - | -172 | -252.5 | -371 | -463.5 |
| FCF margin | - | - | - | - | -2,027.51% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/13/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | -105.1 | -82.72 | -102.9 | -104.9 | - | - | - |
| EBIT 1 | - | -42.7 | -94.42 | -105.1 | -82.77 | -83.99 | -89.52 | -99.28 | -103.5 | -105.8 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -26.04 | -83.94 | -95.21 | -34.97 | -69.47 | -78.34 | -92.98 | -101 | -103.3 |
| Net income 1 | -176.4 | -26.04 | -83.94 | -95.21 | -34.97 | -69.47 | -78.34 | -92.98 | -101 | -103.3 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -8.610 | -0.4000 | -0.8700 | -0.7500 | -0.3600 | -0.6975 | -0.7900 | -0.9100 | -1.005 | -1.035 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 6/15/23 | 8/14/23 | 11/7/23 | 3/28/24 | 5/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 124 | - | - |
| Net Cash position 1 | - | 218 | - | 70.8 | - |
| Leverage (Debt/EBITDA) | - | - | -0.2982 x | - | - |
| Free Cash Flow 1 | - | -172 | -253 | -371 | -464 |
| ROE (net income / shareholders' equity) | - | -138% | -80.9% | -207% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | 6.710 | -2.370 | -0.2900 | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 2.29 | 1 | 1.67 | 2.33 |
| Capex / Sales | - | - | - | - | 10.21% |
| Announcement Date | 4/13/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.06
USD
Average target price
22.5
USD
Spread / Average Target
+454.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.58% | 402M | |
| +16.61% | 122B | |
| +17.75% | 112B | |
| +17.23% | 25.91B | |
| -24.11% | 19.33B | |
| -18.56% | 16.17B | |
| -18.47% | 15.6B | |
| -47.75% | 14.65B | |
| +57.35% | 14.34B | |
| +5.62% | 14B |
- Stock Market
- Equities
- SLRN Stock
- Financials Acelyrin, Inc.
